Physician profile
George S Postma
NPI 1972508455
$3,320.72
in general payments reported to CMS, 2019-2025
33 companies · $665 in 2025
The $665 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $114 · 2021: $63.99 · 2022: $832 · 2023: $835 · 2024: $565 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.53 | 2022-2025 | |
| Amarin Pharma, INC. | $349.48 | 2019-2020 | |
| Lilly USA, LLC | $327.36 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $323.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $226.13 | 2022-2025 | |
| Abbott Laboratories | $181.21 | 2022-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $136.81 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Innovation Technologies INC | $124.99 | 2023 | Irrisept |
| Astellas Pharma US INC | $94.88 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $91.85 | 2022-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $91.50 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lundbeck LLC | $83.68 | 2023-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $74.02 | 2023-2025 | Rexulti |
| Daiichi Sankyo INC. | $72.01 | 2021-2022 | |
| Boston Scientific Corporation | $60.58 | 2021-2024 | Wavewriter Alpha Prime 16, Watchman Flx |
Show all 33 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Postma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.